• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novartis misses on rev, tops sales estimates in Q1

April 25, 2017 By Sarah Faulkner

NovartisShares in Novartis (NYSE:NVS) rose today after the pharmaceutical company met expectations on Wall Street with its 1st quarter earnings, but missed on sales largely thanks to growing pressure from generics to the company’s top-selling chemotherapy, Gleevec.

The company posted profits of $1.92 billion, or 22¢ per share, on sales of $11.53 billion for the 3 months ended March 31, for bottom-line loss of -22% on sales loss of -1% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were $1.13, a penny ahead of consensus on The Street, where analysts were looking for sales of $11.65 billion.

“Novartis delivered another solid performance in the 1st quarter. Growth drivers, including Cosentyx and Entresto, more than offset generic erosion, mainly due to Gleevec,” CEO Joseph Jimenez said in prepared remarks. “The innovation momentum continued in the quarter, led by the launch of Kisqali, and the FDA Priority Review for CTL019 in the US. This reinforces our confidence in our next growth phase, which we expect to start in 2018.”

NVS shares were trading at $76.19 apiece today in afternoon activity, up 2.1%.

In January, Novartis said it was reviewing Alcon and considering a possible sale of the company’s eye care business.

Novartis bought Alcon from Nestle for $52 billion in 2010 under the leadership of former CEO & chairman Daniel Vasella. Alcon’s sales have struggled in recent years and the company has undergone changes to its leadership team. New division head Mike Ball has been charged with halting the company’s revenue slide in case the unit is sold.

Novartis reportedly said it could sell Alcon, spin it off in an IPO or keep it. “We’ve not ruled anything out, all options are on the table,” Jimenez said to Reuters in January. Jimenez told investors to keep an eye out for an update by the end of 2017.

Filed Under: Featured, MassDevice Earnings Roundup, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Novartis

IN CASE YOU MISSED IT

  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS